Preferred Label : Inotuzumab Ozogamicin;
MeSH definition : Immunotoxin that consists of anti-CD22 (CD22 ANTIGEN) humanized monoclonal antibody
covalently linked to the antineoplastic antibiotic CALICHEAMICIN. It is used for the
treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic
leukemia (LEUKEMIA, ACUTE LYMPHOBLASTIC).;
MeSH hyponym : CMC-544; CMC 544;
UNII : P93RUU11P7;
Origin ID : D000080045;
UMLS CUI : C1567130;
ATC code(s)
- Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
Immunotoxin that consists of anti-CD22 (CD22 ANTIGEN) humanized monoclonal antibody
covalently linked to the antineoplastic antibiotic CALICHEAMICIN. It is used for the
treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic
leukemia (LEUKEMIA, ACUTE LYMPHOBLASTIC).
https://www.has-sante.fr/jcms/p_3374919/fr/besponsa-inotuzumab-ozogamicine
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
inotuzumab ozogamicin
infusions, intravenous
antineoplastic agents
precursor b-cell lymphoblastic leukemia-lymphoma
CD22 Positive
recurrence
Refractory B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Recurrent B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
evaluation of the transparency committee
Inotuzumab Ozogamicin
---
https://www.has-sante.fr/portail/jcms/c_2829043/fr/besponsa
https://www.has-sante.fr/portail/jcms/c_2829043/fr/besponsa-inotuzumab-ozogamicine-anticorps-monoclonal-antineoplasique
2018
false
false
false
France
French
orphan drug production
treatment outcome
inotuzumab ozogamicin
Adult B Acute Lymphoblastic Leukemia
antineoplastic agents
antineoplastic agents
precursor b-cell lymphoblastic leukemia-lymphoma
adult
sialic acid binding ig-like lectin 2
precursor b-cell lymphoblastic leukemia-lymphoma
precursor b-cell lymphoblastic leukemia-lymphoma
sialic acid binding ig-like lectin 2
CD22 protein, human
CD22 protein, human
infusions, intravenous
antibodies, monoclonal, humanized
evaluation of the transparency committee
recurrence
guidelines for drug use
survival analysis
Philadelphia chromosome negative
Philadelphia chromosome positive
antibodies, monoclonal, humanized
Inotuzumab Ozogamicin
Inotuzumab Ozogamicin
---
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailTwo.php?lang=fr&linkID=SBD00399
2018
false
true
false
Canada
French
English
drug information
myelodysplastic syndromes
malabsorption syndromes
antibodies, monoclonal, humanized
Inotuzumab Ozogamicin
---
Besponsa - inotuzumab ozogamicin
https://www.ema.europa.eu/medicines/human/EPAR/Besponsa
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
orphan drug production
drug approval
europe
treatment outcome
inotuzumab ozogamicin
Adult B Acute Lymphoblastic Leukemia
antineoplastic agents
antineoplastic agents
precursor b-cell lymphoblastic leukemia-lymphoma
adult
sialic acid binding ig-like lectin 2
precursor b-cell lymphoblastic leukemia-lymphoma
precursor b-cell lymphoblastic leukemia-lymphoma
sialic acid binding ig-like lectin 2
CD22 protein, human
CD22 protein, human
infusions, intravenous
antibodies, monoclonal, humanized
product surveillance, postmarketing
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
drug compounding
Inotuzumab Ozogamicin
antibodies, monoclonal, humanized
Inotuzumab Ozogamicin
---
